Recently a phase I-II trial of vaccination with HLA-A*0201-restricted peptides from prostate specific membrane antigen (PSMA) and survivin was carried out in 20 prostate cancer patients with biochemical failure after surgery or radiotherapy. This evidence concerns the gene BIRC5 and prostate carcinoma.